Circulating miRNA Signature as a Potential Biomarker for the Prediction of Analgesic Efficacy of Hydromorphone

Naoki Kiyosawa 1*, Kenji Watanabe 2,*, Kaoru Toyama 3 and Hitoshi Ishizuka 3

1 Specialty Medicine Research Laboratories I, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan
2 Biomarker Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan; watanabe.kenji.rv@daiichisankyo.co.jp
3 Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd., 1-2-58, Hiromachi, Shinagawa, Tokyo 140-8710, Japan; toyama.kaoru.fb@daiichisankyo.co.jp (K.T.); ishizuka.hitoshi.h8@daiichisankyo.co.jp (H.I.)
* Correspondence: kiyosawa.naoki.wr@daiichisankyo.co.jp; Tel.: +81-3-5740-3412

Received: 12 March 2019; Accepted: 1 April 2019; Published: 3 April 2019

Abstract: No practical biomarkers currently exist for the prediction of the analgesic efficacy of opioids. Previously, we reported circulating miRNA signatures differentially regulated by µ-opioid receptor (MOR) agonists in healthy subjects. We hypothesized that these miRNAs could be potential pharmacodynamic biomarkers to estimate MOR stimulation, and predict the efficacy of opioids; i.e., patients with low MOR stimulation may be more vulnerable to strengthening of the MOR signal upon hydromorphone treatment. To test this hypothesis, plasma samples were obtained from 25 patients with cancer pain prior to the initiation of hydromorphone treatment and the circulating miRNA levels were evaluated, focusing on four miRNAs (i.e., hsa-miR-423-3p, hsa-let-7a-5p, hsa-miR-26a-5p, and hsa-let-7f-5p) and four miRNAs (i.e., hsa-miR-144-3p, hsa-miR-451a, hsa-miR-215, and hsa-miR-363-3p) that were most clearly up and downregulated by hydromorphone and oxycodone. The patients were classified into two classes with putative high and low MOR signal, estimated based on the plasma miRNA signature. A significant correlation was observed between the analgesic efficacy and the putative MOR signal level, and patients with low MOR signal achieved better pain control (i.e., ∆VAS < 0) through hydromorphone. These results suggested that plasma miRNA signatures could serve as clinical biomarkers for the prediction of the analgesic efficacy of hydromorphone.

Keywords: miRNA; biomarker; opioid; cancer pain; hydromorphone

1. Introduction

Opioids have been widely used as analgesics to treat cancer pain [1]. However, considerable individual variability exists in response to opioids, in terms of both efficacy and safety [2]. Unfortunately, technical difficulties in the optimization of opioid prescription have created barriers that prevent patients from receiving adequate pain relief from opioids [3].

One of the factors affecting the response to opioid treatment is the development of tolerance associated with the long-term use of opioids [4]. The mechanism of tolerance development is attributed to pharmacogenetic factors, such as gene polymorphisms in drug metabolizing enzymes or the µ-opioid receptor (MOR) [5], or to the alteration of pharmacological dynamics due to repeated drug exposure. The latter mechanism often results in tolerance to other structurally similar opioids, termed cross-tolerance. Opioid switching aims to circumvent this cross-tolerance by changing to structurally distinct opioid drugs [6–8], but large individual variabilities exist in response to switched opioids.
Thus, a precise medical strategy is desirable to maximize the benefits for individual patients [9], but there are currently no practical biomarkers to predict the analgesic efficacy of opioids.

microRNAs (miRNAs) represent a class of non-coding small RNAs with an average length of 22 nucleotides [10]. miRNAs play crucial roles in various physiological and pathological processes [11], and their dysregulation is associated with disease conditions such as cancers of the liver, cardiovascular system, and central nervous system (CNS), or drug addiction [11–13]. In addition, a number of miRNAs associated with pain signaling are known to exist, and a number of pain-associated miRNAs have been reported in animal models and patients with fibromyalgia, migraine, and osteoarthritis [14–19]. Many miRNA studies in animal models of pain have been performed on neural tissues [15], although some have been performed on body fluids, including blood [20]. For example, extracellular let-7b and miR-599 were found to activate nociceptive sensory neurons to evoke pain via TLR7 and TRPA1 [21], which indicated that extracellular miRNAs can functionally modulate neuronal cells.

Previously, we reported the circulating miRNA signatures in healthy subjects treated with hydromorphone or oxycodone [22]. Although the detailed molecular mechanisms have not yet been clarified, the differentially regulated miRNAs may reflect pharmacodynamic responses to MOR stimulation. Interestingly, some of the upregulated miRNAs in the plasma were reported to negatively regulate MOR functions (e.g., miR-146a-5p and miR-23b-3p), which suggested that the upregulation of these miRNAs may reflect negative feedback in response to MOR stimulation [22]. If this is the case, it may be possible to estimate MOR stimulation from the circulating miRNA signature, thereby enabling the prediction of analgesic efficacy of opioids prior to initiation of treatment (i.e., the greater the stimulation of the putative MOR signal, the lower potential for further MOR stimulation by opioid treatment). To test this hypothesis, we measured the plasma miRNA signatures in patients with cancer prior to the initiation of hydromorphone treatment who had switched from morphine drugs and evaluated whether the miRNA signature was associated with the analgesic efficacy outcome of hydromorphone treatment.

2. Results

2.1. Selection of MOR-Regulated miRNAs from Previous Healthy Subject Study Data

The outline of the miRNA selection procedure is presented in Figure 1. The qPCR panel data comprised 179 miRNAs collected in healthy subject studies, and the data were processed with the internal control normalization method. The lists of differentially regulated miRNA (i.e., \( q < 0.05 \) between 24 h after treatment vs. before treatment with either hydromorphone or oxycodone) are provided in Tables S1 and S2. Four miRNAs, namely hsa-miR-423-3p, hsa-let-7a-5p, hsa-miR-26a-5p, and hsa-let-7f-5p, were commonly upregulated by both hydromorphone and oxycodone. Of these, hsa-miR-423-3p and hsa-let-7a-5p were also identified as commonly upregulated miRNAs using the global normalization method [22], and both hsa-miR-26a-5p and hsa-let-7f-5p were identified as upregulated miRNAs by hydromorphone using the global normalization method [22]. In contrast, 16 miRNAs were commonly downregulated by both hydromorphone and oxycodone. Of these, hsa-miR-144-3p, hsa-miR-451a, hsa-miR-215, and hsa-miR-363-3p exhibited the clearest downregulation by hydromorphone (Figure 1), and all these four miRNAs were also identified as commonly downregulated miRNAs by using the global normalization method [22].
Int. J. Mol. Sci. 2019, 20, x 3 of 12

Figure 1. Selection of miRNAs as putative pharmacodynamic biomarkers reflecting \( \mu \)opioid receptor (MOR) stimulation. Circulating microRNA (miRNA) qPCR data were collected from healthy subjects treated either with hydromorphone or oxycodone [22]. The qPCR panel data were processed by using an internal control-based normalization method. Four and sixteen circulating miRNAs were identified as differentially regulated miRNAs commonly regulated by both hydromorphone and oxycodone. The heat map represents hierarchically clustered \(-\Delta Cq\) values measured in six healthy subjects treated with hydromorphone. Four “MOR-UP” (has-miR-423-3p, has-let-7a-5p, miR-26a-5p, and hsa-let-7f-5p) and four “MOR-DOWN” (has-miR-144-3p, has-miR-451a, has-miR-215, and has-miR-363-3p) miRNAs, which showed the clearest changes in expression, were selected and evaluated for their predictive potentials for the analgesic efficacy of hydromorphone in the study of patients with cancer.

In summary, we selected four upregulated miRNAs (has-miR-423-3p, has-let-7a-5p, miR-26a-5p, and hsa-let-7f-5p; termed MOR-UP miRNAs) and four downregulated miRNAs (has-miR-144-3p, has-miR-451a, has-miR-215, and has-miR-363-3p; termed MOR-DOWN miRNAs) as potential pharmacodynamic biomarkers that reflect MOR stimulation. All eight miRNAs were found to derive from bona fide miRNA genes, according to the MirGeneDB search results [23].

2.2. Study of Patients with Cancer

2.2.1. Demographics of Patients with Cancer

The outline of the study of patients with cancer [24] is presented in Figure 2A, with the demographics of the patients for the miRNA analysis presented in Table 1. There was no significant difference in age, baseline Visual Analog Scale (VAS) score (i.e., average of VAS scores from days –3 to 1), and rescue dose frequency (i.e., from days 1 to 4) between the two dose conversion groups: 21 patients received daily 60 mg/day morphine and four patients received 90 mg/day morphine treatments, who had achieved pain control with morphine and were randomly allocated 1:1 to hydromorphone immediate-release tablets at a conversion ratio of either 1:5 or 1:8. Severe adverse events (SAEs) were recorded for four patients during the study.
Table 1. Demographics of patients with cancer.

| Parameter                           | Dose Conversion Ratio |
|-------------------------------------|-----------------------|
|                                     | 1:5 (N = 12)          |
|                                     | 1:8 (N = 13)          |
| Age, years (mean ± SD)              | 67.5 ± 11.9           |
| Gender                              | 69.2 ± 8.2            |
| Male                                | 10                    |
| Female                              | 9                     |
| Underlying diseases (tumor types)   |                       |
| Urinary / reproductive              | 1                     |
| Lung                                | 2                     |
| Gastrointestinal                    | 3                     |
| Head and neck                       | 6                     |
| Others                              | 2                     |
| Morphine daily dose level (mg)      | 0                     |
|                                     | 11                    |
|                                     | 10                    |
|                                     | 90                    |
|                                     | 1                     |
| Baseline VAS (mm)                   | 14.9 ± 11.9           |
|                                     | 13.3 ± 7.3            |
| Minimum                             | 36.7 ± 6.0            |
|                                     | 25.3 ± 1.8            |
| Maximum                             | 1.7 ± 0.0             |
| Rescue dose frequency during the hydromorphone treatment period (times) | |
| Average ± SD                        | 3.2 ± 0.6             |
|                                     | 1.0 ± 1.8             |
| Maximum                             | 19 ± 6                |
| Minimum                             | 0 ± 0                 |

2.2.2. Analgesic Efficacy of Hydromorphone

The time courses of the VAS scores for the 25 patients are presented in Figure 2B. No association was found between the dose conversion ratio (i.e., 1:5 or 1:8) and the analgesic efficacy potency of hydromorphone, which was consistent with the results for the full patient population reported previously [24]. For two patients, ΔVAS scores could not be calculated due to missing VAS scores during the study.

Figure 2. Study outline and pain intensities in patients with cancer. (A) Study outline. Cancer patients had received treatment with morphine for at least three consecutive days and were switched to hydromorphone treatment. The Visual Analog Scale (VAS) score was recorded once daily as a measure of subjective pain intensity. The Baseline VAS score was calculated as an average of the VAS scores from day −3 to day 1 (before the initiation of hydromorphone treatment). ΔVAS score, which represents the change in pain intensities after hydromorphone treatment, was calculated by the subtraction of the values of Baseline VAS from an average of VAS scores between day 2 and day 4 (Treatment VAS). Blood for miRNA analysis was collected from 25 patients before the initiation of hydromorphone treatment (day 1). (B) The time-course profiles of VAS scores for individual patients. The colors represent patient classes, which were determined from the plasma miRNA signature of the patients as presented in Figure 3A.
2.2.3. Prediction of Analgesic Efficacy of Hydromorphone from Circulating miRNA Signatures

The plasma miRNA levels prior to the initiation of hydromorphone treatment in the 25 patients with cancer are presented in Table 2 (note that plasma miRNA levels were higher when $-\Delta Cq$ values were higher). The patients were classified into two classes by hierarchical clustering analysis of the plasma miRNA levels as presented in Figure 3A. Briefly, the class 1 patients, with high MOR signal scores, exhibited plasma miRNA signatures similar to those in healthy subjects treated with hydromorphone or oxycodone; and the class 2 patients, with low MOR signal scores, exhibited the opposite miRNA signatures to those of class 1 patients.

A putative model for the relationship between the MOR signal score and the potential to exert further analgesic efficacy by hydromorphone treatment is shown in Figure 3B. In this model, class 1 patients, with high MOR signal score, may possess less potential for further stimulation of MOR, resulting in a poor response to hydromorphone. In contrast, class 2 patients with low MOR signal score may possess the potential for further stimulation of MOR, resulting in a good response to hydromorphone.

**Figure 3.** Circulating miRNA signatures of patients with cancer. (A) The miRNA signatures of patients with cancer before the initiation of hydromorphone treatment (i.e., day 1). The heat map of hierarchically clustered $-\Delta Cq$ values for MOR-UP and MOR-DOWN miRNAs is presented; yellow and blue represent high and low blood miRNA levels, respectively. The MOR signal score is calculated from the subtraction of the sum of $\Delta Cq$ for MOR-UP miRNAs from the $\Delta Cq$ of the MOR-DOWN miRNAs. The patients with high and low MOR signal score values were classified into class 1 and class 2, respectively. The overall trend was that class 1 patients had higher $\Delta VAS$ scores than class 2 patients. (B) The putative model for the relationship between the MOR signal score and the potential for hydromorphone to exert analgesic efficacy.
Table 2. – ΔCq values for the selected miRNAs and MOR signal score.

| ID | MOR – UP miRNAs | MOR – DOWN miRNAs | MOR Signal Score | Average ΔVAS | Dose Ratio | SAE |
|----|-----------------|-------------------|-----------------|--------------|------------|-----|
|    | hsa-let-7p5p    | hsa-let-7a-5p     | hsa-miR-423-3p  | hsa-miR-26a-5p | hsa-miR-144-3p | hsa-miR-451a | hsa-miR-215 | hsa-miR-363-3p |           |            |     |
| #1 | −2.7            | −0.3              | −1.0            | 0.2           | −2.8        | 5.0          | −5.6        | −3.5          | 3.0        | 4.3        | 1:5 |
| #2 | −1.7            | 0.9               | −1.3            | 0.4           | −2.0        | 5.4          | −5.0        | −2.9          | 2.7        | 4.3        | 1:8 |
| #3 | −2.0            | 0.3               | −0.9            | 0.1           | −1.9        | 5.7          | −5.1        | −3.5          | 2.2        | 2.7        | 1:5 |
| #4 | −2.3            | 0.2               | −1.3            | 0.3           | −2.1        | 5.2          | −5.1        | −3.3          | 1.6        | −1.0       | 1:8 |
| #5 | −2.5            | −0.1              | −1.3            | 0.2           | −2.0        | 5.8          | −4.7        | −3.2          | 0.5        | 1.7        | 1:8 |
| #6 | −2.0            | 0.2               | −0.9            | 0.1           | −1.6        | 5.7          | −4.1        | −2.4          | −0.2       | 1.7        | 1:8 |
| #7 | −1.9            | 0.4               | −1.3            | 0.2           | −1.6        | 5.9          | −2.7        | −3.3          | −0.9       | 6.0        | 1:8 |
| #8 | −2.1            | 0.1               | −1.1            | 0.3           | −0.6        | 6.3          | −4.4        | −2.8          | −1.2       | 6.7        | 1:5 |
| #9 | −1.3            | 0.5               | −1.8            | 0.1           | −1.3        | 6.6          | −3.6        | −2.4          | −1.9       | NA         | 1:9 |
| #10| −2.5            | 0.0               | −1.2            | −0.2          | −1.3        | 5.8          | −3.1        | −2.8          | −2.4       | 1.0        | 1:5 |
| #11| −2.1            | 0.5               | −1.9            | 0.2           | −0.4        | 6.5          | −4.1        | −2.7          | −2.7       | 2.3        | 1:5 |
| #12| −2.3            | 0.1               | −1.5            | −0.2          | −1.0        | 6.2          | −4.0        | −2.5          | −2.9       | 9.4        | 1:5 |
| #13| −1.9            | −0.2              | −1.8            | −0.5          | −2.5        | 7.0          | −5.1        | −2.5          | −3.0       | 0.7        | 1:5 |
| #14| −1.5            | 1.0               | −1.7            | −0.1          | 6.8         | −2.4        | −3.1        | −3.3          | −3.3       | 2.7        | 1:8 |
| #15| −1.9            | 0.8               | −2.2            | −0.4          | 7.0         | −4.9        | −2.4        | −3.4          | −3.4       | 0.3        | 1:8 |
| #16| −2.6            | 0.0               | −2.1            | −1.2          | 6.1         | −4.0        | −2.5        | −3.4          | −3.4       | 0.0        | 1:8 |
| #17| −3.1            | 0.0               | −1.1            | −0.2          | 5.7         | −0.9        | −3.1        | −4.7          | −4.7       | NA         | 1:5 |
| #18| −2.5            | −0.1              | −1.4            | −0.3          | 6.4         | −3.6        | −1.6        | −4.9          | −13.0      | 1:8 |
| #19| −2.5            | 0.1               | −1.9            | −0.5          | 6.2         | −3.3        | −2.2        | −5.4          | −1.3       | 1:5 |
| #20| −2.6            | 0.2               | −2.2            | −0.5          | 7.5         | −3.4        | −2.1        | −7.2          | −0.3       | 1:8 |
| #21| −2.7            | −0.3              | −1.5            | −0.6          | 7.4         | −3.5        | −1.8        | −7.6          | 7.3        | 1:5 |
| #22| −2.7            | 0.7               | −2.4            | −0.7          | 7.6         | −2.1        | −1.6        | −8.8          | −2.0       | 1:8 |
| #23| −2.5            | 0.1               | −2.5            | −1.2          | 7.4         | −3.4        | −1.1        | −9.4          | 0.0        | 1:8 |
| #24| −3.8            | −0.1              | −3.6            | −1.7          | 7.2         | −3.9        | −2.5        | −9.7          | 0.0        | 1:5 |
| #25| −3.8            | −1.2              | −2.4            | −3.2          | 8.2         | −3.3        | −0.6        | −16.4         | −1.7       | 1:5 |

Negative ΔCq values for the selected eight miRNAs, average ΔVAS scores, and MOR signal scores are presented. MOR signal score is calculated by the subtraction of Σ(ΔCq of MOR-UP miRNAs) from Σ(ΔCq of MOR-DOWN miRNAs). The data are sorted by MOR signal score. NA, data not available. Note that plasma miRNA levels are higher when – ΔCq values are higher. SAE, severe adverse event.
As presented in Figure 4A, significant correlation was demonstrated between ∆VAS and MOR signal score (P < 0.01 by Spearman’s test). In addition, it was demonstrated that patients with ∆VAS > 0 were significantly enriched in class 1 (P < 0.01 by Fisher’s exact test) (Figure 4B).

**Figure 4.** Analgesic efficacy and MOR signal score. (A) Rank order plots for ∆VAS scores and MOR signal scores. Significant rank order correlation was observed between ∆VAS and MOR signal score (P < 0.01 by Spearman’s correlation test). (B) Box plots for ∆VAS scores of class 1 patients (putative poor responders based on MOR signal score) and class 2 patients (putative good responders). Significant enrichment of patients with ∆VAS > 0 (class 1) and ∆VAS ≤ 0 (class 2) was indicated by Fisher’s exact test (P < 0.01).

3. Discussion

In the present study, we tested our hypothesis that the plasma miRNA signature of patients with cancer was predictive of the analgesic efficacy of hydromorphone. We selected eight miRNAs in plasma that displayed the largest expression changes after both hydromorphone and oxycodone treatment in previously published healthy subject studies [22] (Figure 1). In the study of patients with cancer, those who had been treated with morphine were classified into two classes based on their plasma miRNA signatures prior to initiation of hydromorphone treatment (Figure 3A). The patients in class 1 exhibited similar miRNA signatures to those of healthy subjects treated with hydromorphone (i.e., high MOR signal score), which suggested that MOR was stimulated in those patients. We hypothesized that these class 1 patients may possess a lower potential to strengthen the MOR signal by additional hydromorphone treatment (Figure 3B). In contrast, patients in class 2 exhibited opposite miRNA signatures to those in class 1 (i.e., low MOR signal score), which indicated that the MOR signals in these patients were estimated to be low, and that there may be more potential to strengthen the MOR signal by hydromorphone treatment (Figure 3B). In support of this hypothesis, significant correlation was observed between the MOR signal scores and ∆VAS scores (Figure 4A). Furthermore, it was demonstrated that patients with ∆VAS > 0 (i.e., relatively poor responders) were significantly enriched in class 1 (Figure 4B). Collectively, these results indicated that the circulating miRNA signature appeared to reflect the MOR stimulation level, and that the MOR signal score indicated the capacity for further stimulatory potential of MOR prior to the initiation of hydromorphone treatment.

The use of miRNAs as clinical biomarkers offers a number of advantageous characteristics [25]. For example, miRNAs are remarkably stable in body fluids such as blood [26,27]. However, the lack of reproducibility in miRNA signatures among different studies is of concern [12]. This may be partially attributable to the different platforms used for miRNA measurement [28]. To avoid this concern, we used the same qPCR panel platform in both this present study of patients with cancer and our
previous studies of healthy subjects [22]. The selection of a normalization method for the qPCR data of circulating miRNAs is another confounding factor, as there is no currently established ‘gold standard’ normalization method [29]. Nonetheless, both the internal control-based and global normalization methods provided fairly consistent differentially regulated miRNAs from the qPCR data collected in healthy subject studies, which supported the notion that the selected eight miRNAs would provide robust results irrespective of a difference in normalization methods. To the best of our knowledge, this is the first report to present potential blood biomarkers with the ability for objective prediction of the analgesic efficacy of opioids. Our data suggested the promising potential of circulating miRNAs to realize the precision medicine of opioid therapy.

While our findings suggested the intriguing potential of circulating miRNAs as a biomarker to predict opioid efficacy, there were a number of limitations to this study. The first and the most serious concern was that the number of investigated patients was too small to draw robust conclusions. The range of pain intensities represented as VAS scores was quite narrow among patients; accordingly, the overall improvements in pain intensities (i.e., ∆VAS scores) were inevitably small. We invented a very simple model (i.e., MOR signal score) to estimate putative MOR stimulation in the present study; however, with the accumulation of relevant data from a larger number of patients exhibiting a wider range of pain intensities, the development of an optimized prediction model with rational cut-off values should be achieved.

Second, the characteristics of the selected eight miRNAs should be clarified. The biological and pharmacological functions of the selected miRNAs are still largely unknown, although additional data from cutting-edge bioinformatics techniques should provide novel insights, such as target mRNAs and association with diseases [30,31]. In addition, the accumulation of biological knowledge for the miRNAs is required, such as potential circadian rhythm, confounding factors affecting variabilities in expression (e.g., food, comorbidity, age, gender, and cancer type), and the time-course of plasma levels following hydromorphone treatment. In addition, the tissue source of the circulating miRNA is unknown at present; these circulating miRNAs may be derived not only from CNS but from peripheral tissues and even blood cells where MOR is expressed [32,33]. The utilization of peripherally acting MOR agonists with weaker effects on the CNS [34] may partly answer these research questions.

Third, a number of technical uncertainties need to be addressed to establish a robust and reliable clinical diagnostic system. For example, although residual platelets may confound miRNA signatures in the plasma samples [35], we did not perform a centrifugations procedure to remove platelets in our study. While the selected eight miRNAs appeared to successfully provide meaningful information in studies of both healthy subjects [22] and in the present study, further optimization and standardization of experimental procedures should be pursued.

It is unknown if the predictability of the analgesic efficacy of hydromorphone by circulating miRNAs may also apply for other opioid drugs. In our previous study, a number of differentially regulated miRNAs overlapped between hydromorphone and oxycodone [22], but some differences between these drugs were still observed. If these differences reflected drug-specific mechanisms, contents of miRNA signature biomarkers may need to be customized for every opioid drug. Further data accumulation for various structurally distinct opioid drugs may address this question.

In conclusion, we demonstrated the potential of circulating miRNA signatures as biomarkers to predict the analgesic efficacy of hydromorphone in patients with cancer. Further knowledge of both the biological and technical aspects of this process is required to realize the precision medicine of opioid therapies.
4. Materials and Methods

4.1. Previously Published Studies in Healthy Subjects

Selection of miRNAs to Predict Analgesic Efficacy of Hydromorphone

Previously, we measured 179 circulating miRNAs in healthy subjects before and 24 h after a single treatment of either hydromorphone or oxycodone by using a Serum/Plasma Focus microRNA PCR Panel (Qiagen, Venlo, Netherlands), and processed the data by using a global mean normalization method [22]. In general, the global mean normalization method is effective when a sufficient number of target miRNAs are measured [36]; however, practically, the number of target miRNAs is usually small, and in such cases global normalization is not appropriate. Accordingly, in the present study, we re-analyzed the qPCR panel data by using an internal control-based normalization method. For the internal controls used for the normalization process, we selected five miRNAs (miR-425-5p, miR-423-5p, miR-103a-3p, miR-191-5p, and miR-93-5p) based on literature information, including the vendor’s publication [36–38]. The Cq values for the target miRNAs were subtracted from the average Cq values of the five internal controls to obtain the corresponding $\Delta$Cq values. The $\Delta$Cq values for all miRNAs obtained at pretreatment and at 24 h after the drug treatment were subjected to paired t-tests using Benjamini and Hochberg’s method to control the false discovery rate.

From the differentially regulated miRNAs, we selected eight miRNAs (i.e., hsa-miR-423-3p, hsa-miR-26a-5p, hsa-let-7a-5p, hsa-miR-144-3p, hsa-miR-451a, hsa-miR-215, and hsa-miR-363-3p), as presented in Figure 1. Briefly, miRNAs commonly up or downregulated by both hydromorphone and oxycodone in the healthy subjects were determined. The change in expression of these miRNAs at 24 h after hydromorphone treatment in the healthy subjects was calculated by the subtraction of $\Delta$Cq at 0 h from $\Delta$Cq at 24 h after treatment. Four upregulated (“MOR-UP”) and four downregulated (“MOR-DOWN”) miRNAs were selected, as the expression changes in these miRNAs were more distinct than those in the rest of the miRNAs (Figure 1). For visualization purposes, qPCR data from healthy subjects treated with hydromorphone were subjected to hierarchical clustering analysis by using TIBCO Spotfire® (Palo Alto, CA, USA) and presented as a heat map of the $\Delta$Cq values (Figure 1).

4.2. Study in Patients with Cancer

4.2.1. Study Outline

The outline of the study conducted on cancer patients is presented in Figure 2A. Plasma miRNA was measured in a double-blind, randomized comparative study (clinical trial registration ID: JapicCTI-132166), the primary objective of which was to confirm the morphine to the hydromorphone conversion ratio for hydromorphone immediate-release tablets in patients with cancer pain achieving adequate pain control with oral morphine [24]. The study was conducted as a multicenter, active-controlled, randomized, double-blind, parallel-group comparison study, enrolling 71 patients at 39 sites in Japan, in accordance with the ethical principles of the Declaration of Helsinki, the guidelines of Good Clinical Practice, and locally applicable laws and regulations. The study protocol, amendments, and informed consent forms were approved by the Institutional Review Boards of the respective study sites (list of the participating sites can be found in [24]). All subjects provided written informed consent prior to study commencement. miRNA measurements were conducted only for the patients who agreed to be tested. The exploratory miRNA research investigated 25 patients with cancer with an Eastern Cooperative Oncology Group (ECOG) performance status of $\leq 3$. Patients who achieved pain control with morphine 60 mg/day and 90 mg/day for at least three consecutive days were randomly allocated 1:1 to hydromorphone immediate-release tablets (Daiichi Sankyo, Tokyo, Japan) at a dose-converted hydromorphone:morphine ratio of 1:5 or 1:8. Subjects in the conversion ratio 1:5 group received 12 mg/day of hydromorphone when their oral morphine dose was...
60 mg/day during the pre-treatment observation period, and hydromorphone 18 mg/day when their oral morphine dose was 90 mg/day. Similarly, the subjects in the conversion ratio 1:8 group received hydromorphone 7.5 mg/day (oral morphine dose at 60 mg/day during the pre-treatment observation period) or 12 mg/day (oral morphine dose at 90 mg/day during the pre-treatment observation period). Hydromorphone was administered to patients six times daily. The minimum intervals from the last morphine treatment to the initiation of hydromorphone treatment were set as 20 h, 8 h, and 3 h for the morphine drugs prescribed at daily dose frequencies of once daily, twice daily, and six times daily, respectively. Rescue medication by morphine hydrochloride (1/6 of the dose level of that of medicated morphine; i.e., 10 mg morphine hydrochloride for patients medicated with 60 mg/day morphine) was allowed during the study period. The blood samples for miRNA measurement were collected before the initiation of hydromorphone treatment on day 1 (Figure 2A).

4.2.2. miRNA qPCR and Data Analysis

qPCR experiments were conducted at Takara Bio Inc. (Kusatsu, Shiga, Japan). Venous blood was collected into vacuum blood collection tubes containing EDTA-2K as a coagulant, and the plasma samples were prepared. Small RNAs were extracted from 200 µL of plasma by using the miRNeasy Mini Kit (Qiagen, Venlo, the Netherlands) in accordance with the manufacturer’s instructions. Single-stranded cDNA was synthesized by using Universal cDNA Synthesis Kit II (Qiagen). In total, 179 circulating miRNAs were measured by using Serum/Plasma Focus microRNA PCR Panel (Qiagen) and LightCycler® 480 Instrument II (Roche Diagnostics, Basel, Switzerland). The Cq value, which represents the PCR cycle at which the designated threshold amplification level was reached, was determined for all target miRNAs by using GenEx software (Qiagen) in accordance with the manufacturer’s instructions [39]. The target miRNAs with amplification levels that did not reach the designated threshold after 40 cycles of amplification were considered absent and were excluded from further analysis. The normalization of qPCR panel data was conducted by using the internal control method with five miRNAs as internal controls (i.e., miR-425-5p, miR-423-5p, miR-103a-3p, miR-191-5p, and miR-93-5p); these were selected based on literature surveys, including the vendor’s publication [36–38]. The average Cq values for the five internal control miRNAs were subtracted from the Cq values of the target miRNAs to obtain the corresponding ∆Cq values. Hierarchical clustering analysis for the ∆Cq values was performed by using TIBCO Spotfire® software to classify the patients into subclasses of putative high and low MOR signals.

4.2.3. Calculation of MOR Signal Score

The “MOR signal score” represents the putative MOR stimulation based on plasma levels of MOR-UP and MOR-DOWN miRNAs. Briefly, the MOR signal score increased when the plasma levels of MOR-UP were higher and those of MOR-DOWN were lower. The score was calculated from the following:

\[ \text{MOR signal score} = - \sum (\Delta Cq \text{ of MOR-UP miRNAs}) + \sum (\Delta Cq \text{ of MOR-DOWN miRNAs}) \]

4.2.4. Evaluation of Pain Intensity

For pain intensity, VAS score was measured every 24 h (±2 h) during the study to provide an average of pain intensity levels within the last 24 h. Baseline VAS score was determined as the average VAS scores for day −3, day −2, day −1, and day 1 (within 2 h of the first hydromorphone dose). As a measure of the analgesic efficacy of hydromorphone, the average ∆VAS score for each subject was calculated by the subtraction of the Baseline VAS score from average VAS scores for days 2, 3, and 4 (treatment VAS score) (Figure 2A).

4.2.5. Statistical Analysis

Fisher’s exact test was conducted using R (version 3.5.1) to evaluate the enrichment of patients with ∆VAS > 0 for the patient classes 1 and 2, determined based on the plasma miRNA signature
(Figure 3A), with $P < 0.01$ considered to indicate statistical significance. The box plot was drawn by using R. The rank-order correlation between $\Delta$VAS scores and MOR signal scores was evaluated by Spearman’s test using R, and $P < 0.01$ was considered to indicate statistical significance.

**Supplementary Materials:** Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/7/1665/s1.

**Author Contributions:** N.K. and H.I. conceived and designed the experiments; K.T. and H.I. performed the clinical studies; N.K. and K.W. analyzed the data; All wrote, reviewed and approved the paper.

**Funding:** This study was funded by Daiichi Sankyo Co., Ltd.

**Acknowledgments:** The authors are grateful for Taro Tokui for his advice and support in the performance of this study. The authors are also grateful for all of the investigators who provided blood samples for miRNA analysis.

**Conflicts of Interest:** Naoki Kiyosawa, Kenji Watanabe, Kaoru Toyama, and Hitoshi Ishizuka are employees of Daiichi Sankyo Co., Ltd. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**Abbreviations**

- MOR: µ-opioid receptor
- VAS: Visual Analog Scale
- miRNA: microRNA
- CNS: Central nervous system
- ECOG: Eastern Cooperative Oncology Group
- SAE: Severe adverse event

**References**

1. Wiffen, P.J.; Wee, B.; Derry, S.; Bell, R.F.; Moore, R.A. Opioids for cancer pain—An overview of Cochrane reviews. *Cochrane Database Syst. Rev.* 2017, 7, CD012592. [PubMed]

2. Smith, H.S. Variations in opioid responsiveness. *Pain Phys.* 2008, 11, 237–248.

3. Paice, J.A. Cancer pain management and the opioid crisis in America: How to preserve hard-earned gains in improving the quality of cancer pain management. *Cancer* 2018, 124, 2491–2497. [CrossRef] [PubMed]

4. Dumas, E.O.; Pollack, G.M. Opioid tolerance development: A pharmacokinetic/pharmacodynamic perspective. *Aptras* 2008, 10, 537–551. [CrossRef]

5. Owusu Obeng, A.; Hamadeh, I.; Smith, M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. *PharmacoTherapY* 2017, 37, 1105–1121. [CrossRef] [PubMed]

6. De Stoutz, N.D.; Bruera, E.; Suarez-Almazor, M. Opioid rotation for toxicity reduction in terminal cancer patients. *J. Pain Symptom Manag.* 1995, 10, 378–384. [CrossRef]

7. Riley, J.; Ross, J.R.; Rutter, D.; Wells, A.U.; Goller, K.; du Bois, R.; Welsh, K. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. *Support Care Cancer* 2006, 14, 56–64. [CrossRef]

8. Knotkova, H.; Fine, P.G.; Portenoy, R.K. Opioid rotation: The science and the limitations of the equianalgesic dose table. *J. Pain Symptom Manag.* 2009, 38, 426–439. [CrossRef] [PubMed]

9. Bruehl, S.; Apkarian, A.V.; Ballantyne, J.C.; Berger, A.; Borsook, D.; Chen, W.G.; Farrar, J.T.; Haythornthwaite, J.A.; Horn, S.D.; Iadarola, M.J.; et al. Personalized medicine and opioid analgesic prescribing for chronic pain: Opportunities and challenges. *J. Pain* 2013, 14, 103–113. [CrossRef]

10. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* 2014, 15, 509–524. [CrossRef]

11. Wang, J.; Chen, J.; Sen, S. MicroRNA as Biomarkers and Diagnostics. *J. Cell Physiol.* 2016, 231, 25–30. [CrossRef] [PubMed]

12. Ghai, V.; Wang, K. Recent progress toward the use of circulating microRNAs as clinical biomarkers. *Arch. Toxicol.* 2016, 90, 2959–2978. [CrossRef] [PubMed]

13. Im, H.I.; Kenny, P.J. MicroRNAs in neuronal function and dysfunction. *Trends Neurosci.* 2012, 35, 325–334. [CrossRef] [PubMed]

14. Barbierato, M.; Zuso, M.; Skaper, S.D.; Giusti, P. MicroRNAs: Emerging role in the endogenous mu opioid system. *Cns Neurol. Disord. Drug Targets* 2015, 14, 239–250. [CrossRef] [PubMed]
15. Lopez-Gonzalez, M.J.; Landry, M.; Favreaux, A. MicroRNA and chronic pain: From mechanisms to therapeutic potential. Pharm. Ther. 2017, 180, 1–15. [CrossRef] [PubMed]

16. Masotti, A.; Baldassarre, A.; Guzzo, M.P.; Iannuccelli, C.; Barbato, C.; Di Franco, M. Circulating microRNA Profiles as Liquid Biopsies for the Characterization and Diagnosis of Fibromyalgia Syndrome. Mol. Neurobiol. 2016, 54, 7129–7136. [CrossRef] [PubMed]

17. Andersen, H.H.; Duroux, M.; Gazerani, P. Serum MicroRNA Signatures in Migraineurs During Attacks and in Pain-Free Periods. Mol. Neurobiol. 2016, 53, 1494–1500. [CrossRef]

18. Beyer, C.; Zampetaki, A.; Lin, N.Y.; Kleyer, A.; Perricone, C.; Iagnocco, A.; Distler, A.; Langley, S.R.; Gelse, K.; Sessselmann, S.; et al. Signature of circulating microRNAs in osteoarthritis. Ann. Rheum. Dis. 2015, 74, e18. [CrossRef] [PubMed]

19. Bjersing, J.L.; Lundborg, C.; Bokarewa, M.I.; Mannerkorpi, K. Profile of cerebrospinal microRNAs in fibromyalgia. PLoS ONE 2013, 8, e78762. [CrossRef]

20. Qureshi, R.A.; Tian, Y.; McDonald, M.K.; Capasso, K.E.; Douglas, S.R.; Gao, R.; Orlova, I.A.; Barrett, J.E.; Ajit, S.K.; Sacan, A. Circulating microRNA Signatures in Rodent Models of Pain. Mol. Neurobiol. 2016, 53, 3416–3427. [CrossRef]

21. Toyama, K.; Iiyosawa, N.; Watanabe, K.; Ishizuka, H. Identification of Circulating miRNAs Differentially Regulated by Opioid Treatment. Int. J. Mol. Sci. 2017, 18, 1991. [CrossRef]

22. Fromm, B.; Billipp, T.; Peck, L.E.; Johansen, M.; Tarver, J.E.; King, B.L.; Newcomb, J.M.; Sempere, L.F.; Flatmark, K.; Hovig, E.; et al. A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annu. Rev. Genet. 2015, 49, 213–242. [CrossRef]

23. Inoue, S.; Saito, Y.; Tsuneto, S.; Aruga, E.; Ogata, T.; Uemori, M. A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Jpn J. Clin. Oncol. 2018, 48, 442–449. [CrossRef] [PubMed]

24. Lopez-Gonzalez, M.J.; Landry, M.; Favreaux, A. MicroRNA and chronic pain: From mechanisms to therapeutic potential. Pharm. Ther. 2017, 180, 1–15. [CrossRef] [PubMed]

25. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]

26. Park, C.K.; Ju, Z.Z.; Berta, T.; Han, Q.; Chen, G.; Liu, X.J.; Ji, R.R. Extracellular microRNAs activate nociceptor neurons to elicit pain via TRLR7 and TRPA1. Neuron 2014, 82, 47–54. [CrossRef] [PubMed]

27. Fromm, B.; Billipp, T.; Peck, L.E.; Johansen, M.; Tarver, J.E.; King, B.L.; Newcomb, J.M.; Sempere, L.F.; Flatmark, K.; Hovig, E.; et al. A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annu. Rev. Genet. 2015, 49, 213–242. [CrossRef]

28. Van den Borre, S.; et al. Biomarker discovery: Quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med. Genom. 2015, 8, 35. [CrossRef]

29. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]

30. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O’Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513–10518. [CrossRef] [PubMed]

31. Mitchell, A.J.; Gray, W.D.; Hayek, S.S.; Ko, Y.A.; Thomas, S.; Rooney, K.; Awad, M.; Roback, J.D.; Quyyumi, A.; Searles, C.D. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci. Rep. 2016, 6, 32651. [CrossRef] [PubMed]

32. Peng, J.; Sarkar, S.; Chang, S.L. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. Drug Alcohol. Depend. 2012, 124, 223–228. [CrossRef] [PubMed]

33. Belzeaux, R.; Lalanne, L.; Kieffer, B.L.; Lutz, P.E. Focusing on the Opioid System for Addiction Biomarker Discovery. Trends Mol. Med. 2018, 24, 206–220. [CrossRef] [PubMed]

34. Sehgal, N.; Smith, H.S.; Manchikanti, L. Peripherally acting opioids and clinical implications for pain control. Pain Phys. 2011, 14, 249–258. [CrossRef] [PubMed]
36. Exiqon, Biofluids Guidelines (Version 4.0)—Analyzing microRNAs in Liquid Biopsies. Available online: http://www.exiqon.com/ls/Documents/Scientific/microRNA-serum-plasma-guidelines.pdf (accessed on 2 April 2019).

37. Oka, S.; Furukawa, H.; Shimada, K.; Hashimoto, A.; Komiya, A.; Fukui, N.; Tsuchiya, N.; Tohma, S. Plasma miRNA expression profiles in rheumatoid arthritis associated interstitial lung disease. BMC Musculoskelet Disord. 2017, 18, 21. [CrossRef] [PubMed]

38. Wang, J.; Zhu, Y.; Jin, F.; Tang, L.; He, Z. Differential expression of circulating microRNAs in blood and haematoma samples from patients with intracerebral haemorrhage. J. Int. Med. Res. 2016, 44, 419–432. [CrossRef] [PubMed]

39. Exiqon, Data Analysis Guide For the miRCURY LNA™ Universal RT microRNA Ready-to-Use PCR Panels using Exiqon GenEx software Version 3 (February 2014). Available online: https://www.exiqon.com/ls/Documents/Scientific/Exiqon-data-analysis-guide.pdf (accessed on 2 April 2019).

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).